Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy
Public ClinicalTrials.gov record NCT02310594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effect of Radiation Therapy on Tumor Immunity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research trial studies the effect of radiation therapy on tumor immunity. Standard radiation therapy destroys tumor cells. In response to tumor cell death caused by radiation therapy, the body has an ability to stimulate an anti-tumor response (immunity), but this response is often ineffective in shrinking tumor tissue. Collecting samples of blood from patients before, during, and after radiation therapy to study in the laboratory may help doctors learn more about the effects of radiation therapy on anti-tumor response.
Study identification
- NCT ID
- NCT02310594
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2010
- Primary completion
- Aug 8, 2022
- Completion
- Aug 8, 2022
- Last update posted
- Aug 17, 2022
2010 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Malignant Neoplasm trials
Other public records listing Malignant Neoplasm. Sorted by last update posted; newest first. Not a recommendation.
- NCT04410302: Patient-Derived Xenografts to Reduce Cancer Health Disparities Recruiting
- NCT04160390: Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant Active, not recruiting
- NCT07600749: Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) Recruiting
- NCT06818643: A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) Recruiting
- NCT07630974: A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Recruiting
- NCT02479698: Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02310594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2022 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02310594 live on ClinicalTrials.gov.